DDW 2022: Dose Optimization of Vedolizumab After Initial Treatment Failure Did Not Improve Outcomes in Ulcerative Colitis
About 30% of patients eventually experienced clinical response, regardless of dosing regimen
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.